Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 57Terminated 10Unknown 7Recruiting 4Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 8Dermatologic 3Sarcoma 1

Conditions

Melanoma 3Uveal Melanoma 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Dacarbazine × Dermatologic × Clear all
NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Erasca, Inc.

Phase 3 Active not recruiting
78 enrolled
Dermatologic

Melanoma

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDEAYA Biosciences

Phase 2/3 Active not recruiting
420 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00553618 2021-10-29

DTIC

University of Louisville

Phase 2 Active not recruiting
160 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡